Simcere Pharmaceutical Group's (SCR) second-quarter earnings rose 3.6%, topping analysts' estimates, as the Chinese-focused pharmaceutical company' strong revenue gains were essentially offset by climbing costs.
"We are pleased to report strong top-line growth and operating-margin expansion for the second quarter,"
No comments:
Post a Comment